First U.S. Center to Treat a Patient with the new CyberKnife® M6™ System

   First U.S. Center to Treat a Patient with the new CyberKnife® M6™ System

Lancaster General Health Unveils Leading Robotic Radiosurgery System

PR Newswire

SUNNYVALE, Calif., June 13, 2013

SUNNYVALE, Calif., June 13, 2013 /PRNewswire/ --Accuray Incorporated (Nasdaq:
ARAY) announced today that Lancaster General Health in Pennsylvania is the
first U.S. center to treat a patient with the CyberKnife® M6™ System, the most
advanced robotic radiosurgery system in the world and the latest generation of
the CyberKnife System. The new CyberKnife M6 System was designed to provide
clinicians with an enhanced stereotactic radiosurgery/stereotactic body
radiation therapy (SRS/SBRT) solution that targets tumors non-invasively with
precisely delivered, high doses of radiation that spare healthy tissue and
minimize disruption to patients' lives.

The CyberKnife M6 System is a non-surgical option for many patients who have
inoperable or surgically complex tumors, or who seek an alternative to
surgery. In addition to the unmatched clinical capabilities of the previous
CyberKnife System, afforded by non-isocentric, non-coplanar robotic beam
delivery and real-time tracking and automatic correction for tumor motion, the
redesigned M6 System can direct beams from a wider angle around the patient
and provides a streamlined user interface for treatment delivery. The result
is a system that enables the precise radiosurgical treatment of tumors
anywhere in the body with minimal radiation exposure to surrounding healthy
tissue and organs.

"Two weeks ago we successfully treated a patient with a liver tumor with our
new CyberKnife M6 System. We have seen firsthand the positive outcomes we can
achieve for our patients," said Jeffrey S. Eshleman, MD, Director of Radiation
Oncology, Lancaster General Health . "We look forward to bringing this
technology to more patients and providing them with enhanced quality and
highly precise radiation therapy treatments."

"Accuray developed the CyberKnife M6 System to meet the radiation oncologist's
growing need for an efficient, accurate and flexible treatment option that can
be applied to a wide variety of patients," said Joshua H. Levine, president
and chief executive officer of Accuray. "On the heels of adoption in Europe,
we are pleased to be working with Lancaster General Health to lead the way for
patients in the U.S. to receive personalized radiation treatment."

The Ann B. Barshinger Cancer Institute, part of Lancaster General Health, is a
state of the art, two-story, 70,000 square foot facility opening in July 2013
in Lancaster, Pa. The new center will provide advanced technology and
integration of cancer care, bringing medical oncologists, radiation
oncologists, surgeons and other cancer specialists together in one,
centralized location with access to existing services, including the Suzanne
H. Arnold Center for Breast Health. The new Cancer Institute will feature a
new radiation wing with the latest diagnostic and treatment technologies,
including the new CyberKnife M6 System.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited,
to advantages of new technology, clinical applications, clinical results,
patient outcomes, and the Company's leadership position in radiation oncology
innovation. Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from expectations,
including risks detailed from time to time under the heading "Risk Factors" in
the company's report on Form 10-K filed on September 10, 2012, as updated in
our Form 10-Qs filed on November 8, 2012, February 6, 2013, and May 9, 2013
and as updated periodically by our other filings. Forward-looking statements
speak only as of the date the statements are made and are based on information
available to the Company at the time those statements are made and/or
management's good faith belief as of that time with respect to future events.
The Company assumes no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or changes in
other factors affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors should not
place undue reliance on any forward-looking statements.

SOURCE Accuray Incorporated

Website: http://www.accuray.com
Contact: Rebecca Phillips, Public Relations Manager, Accuray, +1 (408)
716-4773, rphillips@accuray.com, or Helen Shik, Schwartz MSL, +1 (781)
684-0770, Accuray@schwartzmsl.com